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Abstract 
Background: The opioid epidemic is a current public health crisis that affects millions of 
Americans. According to the Centers for Disease Control and Prevention (CDC), deaths 
due to opioid overdoses have increased at a rate that has lowered the national life 
expectancy for the first time in decades. Access to opioid treatment for people with 
opioid dependencies allows people an opportunity to seek recovery for their addiction. 
Medication-assisted treatment (MAT) is becoming an effective method of care; 
combining behavioral therapy and medication. The federal government permits 
clinicians that are not apart of opioid treatment programs to apply for waivers that allow 
them to individually prescribe MAT drugs. Thus, physician capacity—the proportion of 
physicians available to prescribe MATs—affects access to this type of care. However, 
physician capacity to prescribe MATs are rarely touched upon in the literature, even 
though it is a large factor in increasing access to care.  
Method: The purpose of this study is to examine the association between physician 
capacity to prescribe MATs and related policy and public programs. This is a 
retrospective observational study that examines physician capacity trends from 2007 to 
2016. Using data from the Substance Abuse and Mental Health Services, the number of 
opioid treatment programs and physicians with specific waivers to prescribe MATs were 
counted and standardized by population. The State Drug Utilization data from the 
Centers for Medicare & Medicaid Services, age-adjusted opioid overdose death rates 
from the Centers for Disease Control and Prevention, and other variables studied were 
also examined by state and by year. Treatment capacity and mortality variables were 
divided into quartiles by year.  
Results:  High capacity states had more growth in buprenorphine waivers between 
2007 and 2016. High capacity states were also more likely to have expanded their 
Medicaid programs. States with low physician capacity to treat with MAT were less 
likely to have expanded their Medicaid programs and had the lowest proportion of 
state level substance use risk assessments policies as a requirement or 
recommendation to physicians before prescribing pain medication. 
Conclusion: Understanding the commonalities of high capacity states may offer an 
insight to possible policy interventions to confront the opioid epidemic. Furthermore, 
research that blends the worlds of public policy and public health are important for 
combatting this multifaceted problem. 
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Introduction 
 Deaths attributed to accidental opioid overdose have significantly increased in 
America over the past two decades. According to the Centers for Disease Control and 
Prevention (CDC), overdose deaths from prescription opioid drugs and illicit opioid 
drugs like heroin are five times the rate in 2016 that they were in 1999 (Hedegaard, 
Warner, & Miniño, 2017). This trend of increased mortality is referred to as the opioid 
epidemic. The opioid epidemic has surged as each year more Americans die from 
unintentional overdoses and the epidemic has been declared a public health 
emergency.  
 It is crucial that there are more effective prevention efforts to reduce the health 
impacts of the opioid epidemic as well as access to treatment and recovery programs 
for those who experience opioid dependencies. There are many discrepancies in the 
current drug treatment landscape. With geographical and organizational barriers, it is 
necessary to ensure those entering drug treatment for opioids are experiencing 
comprehensive forms of care. Medication-assisted treatment (MAT) is considered best-
practice for opioid dependencies. MAT is seen as more inclusive than traditional forms 
of detoxification and treatment. 
Background 
Medication-assisted treatment (MAT) utilizes both behavioral therapy and 
medication that affects opioid receptors. This form of treatment has shown to be 
effective for treating opioid dependencies. This type of treatment has also been shown 
to improve overall quality of life, including lowering risks of infectious diseases, 
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decreases the risk for relapse, increases in employment, and overall patient experience 
(SAMHSA, 2018). MAT typically uses one of three drugs—methadone, buprenorphine, 
and naltrexone—to correct chemical balances in in the brain. Methadone is an opioid 
agonist, which binds to opioid receptors like other prescription opioids and heroin but 
releases chemicals at a steadier, more controlled rate. Buprenorphine is similar to 
methadone; the medication relieves cravings and withdraw symptoms. However, 
buprenorphine is a partial-opioid agonist and will only produce moderate chemical 
responses. Buprenorphine also lowers the risk of misuse and overdose compared to 
methadone due to the chemical composition. Naltrexone is used in MAT as an 
injectable drug that is administered once a month. As an opioid antagonist, naltrexone 
blocks opioids from attaching onto receptors and reduces cravings. The Substance 
Abuse and Mental Health Services Administration states that when these medications 
are combined with counseling, this approach can effectively treat addiction (SAMHSA, 
2018). 
These medications are highly regulated; both methadone and the injectable form 
of naltrexone must be administered at accredited opioid treatment programs (OTP). 
Buprenorphine may also be prescribed at an OTP, but can also be part of an outpatient 
treatment plan. Due to the Drug Addiction Treatment Act of 2000, clinicians are able to 
prescribe buprenorphine in outpatient settings by obtaining federal waivers (Drug 
Addiction Treatment Act of 2000). Physicians who obtained these waivers were able to 
initially treat up to 30 patients at a time, starting in 2002. Amendments in 2007 and 2017 
allowed physicians to raise the patient limit to 100 and 275 at a time, respectively. 
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These increases can be granted after the physician has seen the previous limit for at 
least one year.  
This has dramatically improved the access to MAT. Adoptions of these waivers 
and increases in OTPs have allowed more individuals to seek treatment for opioid 
addiction. However, the growth of treatment has not been evenhanded and due to 
unequal policies, health insurance programs, and other structural factors, many 
individuals are not able to receive medication-assisted treatment. The purpose of this 
study is to analyze the variations of MAT access by focusing on physician capacity 
across the states and the District of Columbia. Physician capacity is described as the 
proportion of physicians available to prescribe MATs—through OTPs or federal waivers. 
Specifically, Medicaid program expansion, Medicaid drug utilization and reimbursement, 
specific opioid prescribing polices, and overdose death rates were studied. Examining 
how state-level factors correlate to relatively higher or lower capacities can provide 
guidance for future policy solutions.  
Literature Review 
 
Underutilization of medication-assisted treatment  
 
As the opioid epidemic has become more salient, researchers are producing 
work to reflect current practices, difficulties, and advancements in medication-assisted 
treatment and its utilization. One major issue is that MAT is underused. This is partly 
related to limited access of opioid treatment programs and physician offices. A national-
level review published in the American Journal of Addictions found that potential 
patients have difficulties accessing substance abuse treatment in 85% of counties 
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(Levin et al, 2016). That result was referring to any kind of substance abuse treatment, 
not specifically MAT, which is even scarcer. Another study calculated that less than half 
of counties have a waivered physician that is able to prescribe buprenorphine, and 
these counties contain over 90% of all citizens (Rosenblatt et al, 2015). This leaves 
thirty million people in counties without a waivered physician—most of them resided in 
rural counties.  
The Food and Drug Administration (FDA) has approved the current MAT drugs to 
be effective with opioid dependency treatment; however they remain not fully utilized. 
Among clinicians with buprenorphine waivers, about half (44%-66%) are actively writing 
prescriptions for the drug, and only a small percentage of clinicians are reaching their 
maximum limit of 30 or 100 patients at a time (Jones et al, 2015).   
Enhancing physician capacity may address the issue of MAT underutilization. As 
the number of potential providers increase, individuals seeking treatment may be able to 
gain access through their insurance network. Creating closer proximity to MAT 
treatment sites may also allow for greater utilization as millions of Americans live in 
areas without these services currently. There is also the issue that there are current 
office-based physicians that are not reaching their prescribing limits. These may be due 
to the physician being outside of individual’s provider networks or be a burden for 
patients to access. For example, a psychiatrist that can prescribe buprenorphine may 
have high copays or not be included in insurance plans. That is why increasing the pool 
of providers may increase utilization of medication-assisted treatment. However, the 
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current literature has not suggested an optimal threshold for the number of MAT 
providers.  
Relevant policies and programs 
 The application of medication-assisted treatment has overwhelming 
documentation to be underutilized, and recent policies have been executed to combat 
that. The Drug Addiction Treatment Act (DATA 2000) mentioned previously has been a 
major policy targeting treatment expansion and access to buprenorphine-assisted 
treatment. Information from the Drug Enforcement Agency states that in 2002—the first 
year of the DATA 2000 implementation—around 2,000 physicians applied for waivers, 
and by 2011 over 20,000 physicians had applied (Knudsen, 2015). One rationale of 
DATA 2000 is to decrease geographical barriers to treatment and create more 
integration of addiction treatment with other forms of chronic disease care (Jones et al, 
2015). In theory, a physician in a primary care setting who notices a lack of local opioid 
treatment facilities can apply for a buprenorphine waiver to provide more access to care. 
A limit to this rationale is the reality of medically underserved areas in the United 
States. This policy was partly designed to increase treatment access in areas without 
opioid treatment facilities or other existing forms of treatment. However, these typically 
include areas that have shortages of medical providers. Without available physicians, 
areas will remain to lack access to medication-assisted treatment.  
Adoption of waivers by physicians may be contingent on other political and 
structural factors. Medicaid programs have been cited to correlate with access to opioid 
dependency treatment. In addition, studies have linked differences in Medicaid 
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coverage as a factor in MAT availability (Jones et al, 2015). Under the Patient 
Protection and Affordable Care Act of 2010, states had the option to expand their 
Medicaid programs. These expansions would raise health insurance eligibility to 
households with income at or below 138% of the federal poverty level, which would 
provide coverage to a population with statistically high opioid addiction (Wen et al, 
2017). As of 2016, 31 states and the District of Columbia opted to expand their 
programs. A quasi-experimental study on the effects of Medicaid expansion in 2014 
found that expansion states increased buprenorphine spending through Medicaid by 
49.9% (Wen et al, 2014). The same study concluded that expansion attributed to 70% 
more buprenorphine prescriptions.  
Disparities in access and utilization 
There are parts of the country with shortages in healthcare professionals and 
states that have not expanded their Medicaid programs; state level factors like these 
create inequalities in access to medication-assisted treatment. The lack of integration of 
mental health and other forms of medicine has also created barriers and substandard 
health outcomes (Levin et al, 2016). Regional differences have shaped many of the 
present issues in access to opioid use treatment. Opioid treatment programs are 
clustered/concentrated in urban areas (Stein et al, 2015), As opioid treatment programs 
have increased in metropolitan areas, rural areas have experienced large increases in 
physicians obtaining waivers (Knudsen, 2015). However, there is still a disparity 
between urban and rural access to addiction treatment.  
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In another context of geography, there are also regional differences to treatment 
potential. A state level analysis reported that states in the Northeast had statistically 
significantly more options for buprenorphine treatment than other regions, with the 
Midwest having the least (Knudsen, 2015). When examining federal buprenorphine 
waivers specifically, the irregularities between states and regions may suggest large 
differences in physician attitudes and behaviors. A paper produced by the Office of 
Public Health Strategy and Analysis of the FDA examined physician barriers in 
applications for federal waivers. The findings revealed “barriers include willingness to 
prescribe, low provider confidence in addressing addiction, limited access to addiction 
experts, lack of institutional or office support, lack of behavioral health services, and 
reimbursement concerns (Jones et al, 2015).” Both provider and patient difficulties are 
important to understand in order to address the under utilization of MAT during the 
opioid epidemic. 
Possible solutions 
The current literature poses some potential solutions. Expanding the pool of 
potential providers is a key suggestion. One way to increase the number of 
buprenorphine-waivered practitioners is to amend the law to include physicians 
assistants and nurse practitioners (Levin et al, 2016). Allowing physicians assistants 
and nurse practitioners to prescribe MAT would be a positive step towards integrating 
addiction treatment in medical settings and could benefit areas that are medically 
underserved. Currently, psychiatrists are the group of doctors with the highest rate of 
buprenorphine waiver attainment, followed by pain management, physical rehabilitation, 
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family medicine, and internal medicine (Rosenblatt et al, 2015). Physician specialty may 
be another source for strategies to expand MAT. Physician capacity to prescribe 
buprenorphine has been associated with economic improvements and the number of 
specialists in an area increases with income (Knudsen, 2015).  
The climate surrounding medication-assisted treatment impacts policy solutions 
as well. Higher proportions of treatment facilities may be indicative of more supportive 
state and local governments, who in turn allocate more resources to opioid dependency 
treatment (Knudsen, 2015). Since behavioral health in general is legislated and 
regulated separately from other types of medical practices, understanding political 
feasibility and identifying stakeholders is key in advocating for MAT expansion. 
Government officials and clinicians may be unaware of the outcomes of MAT utilization. 
Targeting institutions and educating healthcare professionals about addiction treatment 
may increase support (Jones et al, 2015). Stigma is an ongoing hurdle in the realm of 
addiction treatment and educating both practitioners and administrators can efficacy in 
MAT.   
Focusing on buprenorphine waivers is another strategy. Increasing the number of 
waivered physicians is the goal of many public health professionals. More physicians in 
rural areas have received waivers than physicians in urban counties (Stein et al, 2015). 
As more research is done on MAT, more providers may gain the confidence to apply for 
waivers. However, there may be outcome differences in 30-patient and 100-patient 
waivered physicians and their effect on improving access. Researchers from the RAND 
Corporation, a national policy think tank, studied the buprenorphine dispersion between 
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the two capacities and found that 100-patient waivered physicians had substantially 
more impact on growth than 30-patient waivered physicians (Stein et al, 2015). In the 
public health sphere with scarce resources, focusing specifically on increasing 100-
patient waivered physicians—and not necessarily increasing the total number of 
waivered physicians—may be a more beneficial investment. Policies that give support to 
30-pateint waivered physicians to increase their number of patients by apply to 100-
patient waivers and retain providers in the market are viable options. The current 
maximum capacity for waivered physicians is 275 patients. Once research can measure 
the effects of this higher capacity it can be postulated if larger maximums are another 
strategy for treatment growth. This study aims to examine state variations in treatment 
capacity while taking into account the relevant policies, inequalities, and possible 
solutions.  
Methods 
 
Data 
 
 This is a retrospective observational analysis. This study examined data from 
2007 to 2016 in order to assess long-term policy implications and their connections to 
physician capacity. The unit of analysis is state-year. The Substance Abuse and Mental 
Health Services Administration (SAMHSA) provided public information on the number of 
DATA-waivered physicians for 30 and 100 patients for each state. The National Survey 
of Substance Abuse Treatment Facilities (N-SSATS) from SAMHSA documented the 
number of opioid treatment programs that offered some form of medication-assisted 
treatment (buprenorphine, naltrexone, and/or methadone). N-SSATS data was taken 
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from 2013 to 2016 due to changes in reporting previous years of the survey that would 
have led to inconsistencies in the analysis. Numbers of patient waivered physicians and 
opioid treatment programs account for physician capacity variables.  
A major dataset that was used was the Centers for Medicare & Medicaid (CMS) 
State Drug Utilization Dataset that had record of the number of prescriptions made per 
year for each state and the District of Columbia. The State Drug Utilization Datasets 
also included reimbursement information that this study analyzes. Data from 2007 to 
2016 created variables for utilization and reimbursement with the total Medicaid and 
non-Medicaid number of prescriptions made and the total Medicaid and non-Medicaid 
amount reimbursed to pharmacies in the state that, respectively.  
This study was interested in quantifying a state’s burden related to the opioid 
epidemic. Burden was extrapolated from opioid-related overdose mortality that would 
capture overdoses from prescription drugs and illicit drugs like heroin and illicit fentanyl. 
Opioid overdose mortality data was gathered from the Centers for Disease Control and 
Prevention (CDC) National Center of Injury Prevention and Control and were age-
adjusted and were standardized per 100,000 people. Overdose mortality was collected 
for each state and the District of Columbia from 2013 to 2016.  
Analytic Strategy 
To gain a better understanding of the factors that impact physician capacity, 
multiple variables were used in this study. The variables created to measure physician 
capacity were transformed into rates of physicians with 30-patient waivers, the rate of 
physicians with 100-patient waivers, and rate of opioid treatment programs, all 
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population-adjusted per 1 million residents. Total number of buprenorphine, naltrexone, 
and methadone prescriptions and amount reimbursed were sorted from the CMS State 
Drug Utilization datasets and then population adjusted per 1 million residents. Yearly 
state populations were documented from the United States Census Bureau annual 
estimates and were used for all population-adjusted calculations. 
This study in interested in other possible policy influences. State Medicaid 
program expansion was recorded for the states that choose to expand programs with 
1115 waivers during the study period. Prescription drug monitoring programs are 
another topic focused on in the literature that is seen as a factor when prescribing 
MATs. Using data from the National Alliance For Model State Drug Laws (NAMSDL), it 
was noted if a state had a requirement/recommendation that physicians assess patients 
for substance use disorders (SUD) before prescribing pain medications. It was logged if 
states and the District of Columbia did or did not have these 
requirements/recommendations in 2016. Both expansion and prescribing variables were 
coded as binary.  
Analysis 
 Graphs were created to illustrate longitudinal trends of MAT treatments by state 
and by physician capacity. To accomplish this, 30-patient waiver, 100-patient waiver, 
opioid treatment program, and mortality data from each state and D.C. were organized 
into quartiles by year. Quartile 1 would represent states with the lowest averages and 
Quartile 4 representing states with the highest averages. For example, a state with a 
relatively high rate of overdose deaths would be in Quartile 4 that year.  
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The statistical software Stata was used to perform hypothesis testing. Two 
sample t-tests were performed to examine differences in capacity means with reference 
to Medicaid expansion and SUD risk assessment policies. For hypothesis testing, 95% 
confidence intervals were used.  
Results 
 
 The main outcome investigated was the variability of waivered physicians and 
opioid treatment programs in states. Longitudinal trends in waivered physician capacity 
were graphed. Among 30-patient waivered physicians, there was a steady increase in 
Quartile 1, 2, and 3 groups (Figure 1). The trends seem to follow almost uniformly. 
However, the Quartile 4—highest waivered—group appears to have a distinct pattern of 
growth that the lower three groups do not share. Between 2007 and 2016, the mean 30-
patient waiver capacity grew from 17.3 waivered physicians per 1 million residents to 
42.3; a 144% increase. In the same time period, the mean 30-patient waiver rate for 
Quartile 3 increased from 9.9 to 16.9 (70% increase). Quartile 1 and 2 also increased 
from 7.0 to 11.3 (61% increase) and 3.6 to 6.2 (72% increase), respectively.  
 Rates of physicians waivered per 1 million residents for up to 100 patients also 
fluctuated during the study period (Figure 2). 2007 was the first year physicians had the 
ability to increase their patient prescribing limit form 30 to 100. Overall, after 2007 there 
was an immediate drop in the number of 100-patiet waivered physicians followed by a 
general increase. There is no apparent policy reason for the attrition.  Between 2008 
and 2016 the quartiles experienced shifts in 100-patient waivered physician rates from 
0.65 to 1.6, 1.4 to 4.1, 2.2 to 6.2, and 4.2 to 13.1, respective to Quartile 1, 2, 3, and 4. 
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Additionally, the last few years of the study observed smaller gains in 100-patient 
waivers.  
Mirroring the Quartile 4 trends of 30-patient waivers, 100-pateint waivered 
physician rates in Quartile 4 are dramatically larger in comparison to other quartiles. It 
appears that high capacity states are more effective at increasing the number of total 
waivered clinicians. In 2015 and 2016, eight of the thirteen states in Quartile 4 for 30-
patient waivered physicians were also considered high capacity states (Quartile 4) for 
100-patient waivers. These states are Connecticut, Massachusetts, Maine, New 
Hampshire, New Mexico, Rhode Island, Vermont, and West Virginia. 
 Also notable, of those eight states all but Connecticut are in the Quartile 4 for 
rates per 1 million residents of OTPs that utilize MAT.  This correlation is important in 
understanding the nuances of high capacity states. The rationale of the federal waivers 
was to increase access to MAT in areas where inpatient and intensive outpatient 
programs were not as accessible. However, the states with the most treatment facilities 
per residents have surpassed others in office-based physicians obtaining these federal 
waivers. The existence of opioid treatment programs may have underlying factors that 
influence the attainment of waivers. State run programs and policies like Medicaid 
programs, funding and reimbursement, and general attitudes towards mental health and 
substance use disorders may be root causes as to why these two separate delivery 
systems surge simultaneously. Regional variations in physician capacity also persist, as 
New England is overrepresented among these seven states.  
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An element of these trends that is significant when discussing the impacts of 
policy on medication-assisted treatment access is the Medicaid expansion 
implementation under the Affordable Care Act. At the beginning of 2014, 26 states and 
the District of Columbia had opted to expand their states’ Medicaid coverage to include 
individuals below 138% of the poverty line. Of these states, California, Minnesota, and 
New Jersey had expanded programs since 2011. The growth of Medicaid programs 
may attribute to the sharp increase of newly waivered physicians, specifically in high 
access states. As this new cohort became able to gain health insurance, they would 
have finally been able to afford addiction treatment and the medication prescriptions for 
MAT. In 2014 and 2015, all states in Quartile 4 for 30-patient waivered physicians but 
Arkansas, Maine, and Tennessee had expanded Medicaid programs. In 2016, only 
Arkansas and Maine were non-expansion states in Quartile 4; Tennessee was no 
longer in Quartile 4. Using a two-sample comparison of means between expansion and 
non-expansion states in Quartile 4 did not yield statistically significant results, because 
on the small sample size of non-expansion states.  
 Differences in average physician capacity for expansion and non-expansion 
states were explored. In 2014, the mean rate of 30-patient waivered physicians per 1 
million residents for expansion states—regardless of quartiles—was statistically 
significantly larger than the mean number of 30-patient waivered physicians for non-
expansion states (12.01 vs. 7.60, p=0.0097). There was not a statistically significant 
difference between 100-patient waivers between groups that year (Table 1). In 2015, 
the mean number of 30-patient waivered physicians for expansion states was 
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statistically significantly larger than the mean rate of 30-patient waivered physicians for 
non-expansion states (14.92 vs. 9.36, p=0.0264). The average number of 100-patient 
waivers was also statistically significantly more for expansion states (6.39 vs. 3.92, 
p=0.0180) (Table 2). In 2016, the mean number of 100-patient waivered physicians for 
expansion states was statistically significantly larger than the mean rate of 100-patient 
waivered physicians for non-expansion states (7.22 vs. 4.73, p=0.0333). There was not 
a statistically significant difference between 30-patient waivers between groups that 
year (Table 3). Lastly, the average rate for opioid treatment programs with access to 
MAT was not found to be statistically different among Medicaid expansions group. 
 The proportion of states that chose to expand Medicaid eligibility by quartile for 
2014, 2015, and 2016 were also examined. A presumption was that states that 
increased their Medicaid programs would be more represented in high capacity states 
since millions of new patients would have gained access to medication-assisted 
treatment. Using two sample proportion tests, expansion and non-expansion groups 
were compared by quartile-year for 30-patient waivers (Table 4) and 100-patient 
waivers (Table 5). For both 2016 and 2014, there were statistically significantly more 
Medicaid expansion states than there were non-expansion states in Quartile 4 for 30-
patient waiver rates. Also for 30-patient waiver rates, there were statistically significantly 
more non-expansion states than there were expansion states in Quartile 1 in 2015. For 
2014, there were statistically significantly more non-expansion states than there were 
expansion states in Quartile 2 for 30-patient waiver rates. For 100-patient waiver 
quartiles, there were statistically significantly more Medicaid expansion states than there 
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were non-expansion states for Quartile 4 in 2016. These tests indicate that 2016 had 
significantly more Medicaid expansion states high capacity quartiles for both patient 
prescribing limits. The role of Medicaid expansion on access to medication-assisted 
treatment may be starting to produce noticeable beneficial effects.  
When examining physician capacity rates and a state’s requirement or 
recommendation that physicians screen for substance abuse risk before prescribing 
pain medication, patterns emerged. In 2016, only four of the thirteen states (30.8%) in 
Quartile 1 for total waivered physician rate (both 30-patient and 100-patient combined) 
had the requirement/recommendation. In Quartile 2, the proportion increases to ten 
states (76.9%). Quartile 3 has nine states (69.2%) and Quartile 4 has ten states 
(76.9%). An almost equal number of states in the top three quartiles have introduced 
this policy into their prescription drug monitoring programs, however the majority lowest 
capacity states in 2016 have yet to. Perhaps lawmakers in these low capacity states do 
not see these screening as necessary, and the lack of priority put on substance use 
disorder prevention and intervention feeds into the relatively low numbers of federally 
waivered physicians that can supply MAT.  
 There was no statistically significantly difference in rates of 30-patient waivers 
between states that have the assessment policy and states that do not. However, the 
average number of 100-patient waivers was statistically significantly more for states that 
had the prescribing procedure as a requirement or recommendation. (7.24 vs. 4.56, 
p=0.0249). Any correlation between the two groups and rates of opioid treat programs 
were not explored as this policy was not relevant for clinicians in that setting (Table 6).  
State variations in physician capacity to treat opioid dependencies with medication-assisted treatment	   19 
 This policy may be seen as helpful in increasing medication-assisted treatment 
utilization. A possible rationale could be that with the increased screening for substance 
use disorder, there will most likely be more diagnoses for opioid dependency. More 
SUD diagnoses would lead to more people seeking treatment and a greater increase in 
physician capacity for treatment. Another explanation may be that state policymakers 
feel more comfortable enacting the policy if there is a sufficient pool of MAT providers in 
that state. That way, providers can link individuals with opioid dependency risk to care.   
 Opioid-related overdose mortality had the tendency to increase with the rate of 
federal waivers in a state. For states with the highest 30-patient waiver rates in 2016, 
the mean age-adjusted opioid overdose mortality (per 100,000) was statistically 
significantly higher than average mortality of the lowest two quartiles (Table 7).    As 
mentioned previously, opioid overdose mortality is being used as a measure for the 
opioid burden afflicted on each state and D.C. It could be that as the opioid epidemic 
becomes more salient in a state, a clinician is seeks out these federal waivers as an 
opportunity to mitigate some of the disease burden.   
 Age-adjusted overdose mortality averages by quartile look similar for 100-patient 
waiver data for 2016 (Table 8). The mean overdose death rate for Quartile 4 was 31 
deaths per 100,000 people. This is statistically significantly different than the means of 
Quartile 1 (13.3) and Quartile 2 (18). The average mortality rate for Quartile 3 (23.1) 
was also statistically significantly higher than the mean for Quartile 1.  
 These results demonstrate a positive correlation between opioid overdose 
mortality and physician capacity to treat opioid dependency with MAT. States with 
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higher opioid-related overdoses tend to have higher physician capacities of both patient-
prescribing limits. In future modeling of what drives buprenorphine waiver adoption, 
opioid disease burden should be acknowledged. Perhaps, another added social benefit 
to buprenorphine waivers are that it gives physicians an opportunity to feel efficacious 
about an issue surrounds them. Clinicians in higher mortality states may feel more 
impacted by the opioid epidemic and utilize these federal waivers more often.    
An attempt was made to explore the phenomenon of reverse causality, where it 
could be argued that states that are more affected by the opioid epidemic are utilizing 
buprenorphine, naltrexone, and methadone more. Taking states in the highest quartile 
for overdose morality in 2016, the rates of MAT utilization and pharmacy reimbursement 
were compared (Figure 3). Both reimbursement and utilization were population-adjusted 
per 1 million people. There is obvious variability between high mortality states. Though 
these states and D.C. have similar rates of age-adjusted overdose deaths, the 
frequency of MAT prescriptions ranged from 14,800 per 1 million residents in D.C. to 
84,300 in West Virginia. Reimbursement—and primarily reimbursement rates—of these 
medications also fluctuate between high mortality states. The amount of money 
pharmacies were reimbursed for MAT drugs in each state were also adjusted by 
population. In D.C., the population-adjusted rate for drug reimbursement was 
$484,779.77, but was $13,243,211.20 for West Virginia. Of these states, all but one—
Delaware—were above the 50th percentile for both 30-patient and 100-patient waiver 
rates.  
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The same variability was seen among utilization and reimbursement rates of low 
mortality states, but on a smaller scale (Figure 4). Frequency of MAT prescriptions 
ranged from 574 per 1 million residents in South Dakota to 6,100 in Minnesota. When 
looking at population-adjusted drug reimbursement, South Dakota paid back $90475.16 
per 1 million residents to pharmacies while Minnesota paid back $1,356,773.78 per 
million residents. Of the thirteen low mortality states, ten of them were under the 50th 
percentile for both 30-patient and 100-patient waiver rates. This illustrates than although 
utilization and reimbursement rates were diverse across states with similar opioid 
burden, general trends of physician capacity and utilization/reimbursement were linear. 
Discussion 
 
 This study aimed to analyze access to medication-assisted treatment and how 
various federal and state policies have fueled current access inequalities at the state 
level. States with the highest rates of buprenorphine waivers and opioid treatment 
programs appear to habitually improve while lower capacity states remain rather 
stagnant in access outcomes. As shown, high capacity states had more growth in both 
30-patient and 100-patient buprenorphine waivers between 2007 and 2016. High 
capacity states were also more likely to have expanded their Medicaid programs. 
Additionally, states with low physician capacity to treat using MAT were less likely to 
have expanded their Medicaid programs and had the lowest proportion of state level 
SUD assessment policies as a requirement or recommendation to physicians before 
prescribing pain medication.   
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 These observations reinforce findings of past research. Medicaid program 
expansion appears to play a role in treatment access and utilization. Also, efforts made 
in prioritizing substance use treatment in legislatures are impactful and may be 
indicators of attitudes about addiction and treatment. Like past studies have implied, 
access to MAT varies by region. Most of the high capacity states were represented in 
the Northeast region of the country, but the span and recency of this study has added 
more depth to that claim. Not all Northeast states have the same physician capacity rate 
and as Midwest states have experienced increases in mortality from the opioid crisis, 
states like Ohio and West Virginia have moved into high-capacity groups.  
 It is important to understand that the purpose of this research—and all research 
in the field of addiction treatment—is to better assess both the personal barriers and 
larger structures that impact patient outcomes. Access is a key factor in this discussion, 
but increasing access is not the panacea to the opioid crisis. The physical, mental, and 
social consequences of addiction are interlocked and although an improvement to one 
area may relieve issues in another, there are other elements that should be examined.  
 It is imperative to evaluate health outcomes through a policy lens. Evidence-
based policy implementations are going to define how the United States combats the 
current opioid epidemic. Through this research, it is shown that there are current 
policies and programs that are beneficial to increasing medication-assisted treatment 
access. Policies may lag in initial outcome observations, but there are some impacts 
being made already in opioid dependency treatment and the health care market in 
general. It would be advantageous for future research to create predictive models that 
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can be tested to gauge what policies and programs have stronger causal relationships 
with MAT access. Understanding the commonalities of high capacity states may offer an 
insight to possible policy interventions to confront the opioid epidemic. Furthermore, 
research that blends the worlds of public policy and public health are important for 
combatting this multifaceted problem.  
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Appendix 
 
Figures 
 
Figure 1. 30-Patient Waiver Capacity Trends by Quartile (2007-2016). 
 
 
Figure 2. 100-Patient Waiver Capacity Trends by Quartile (2007-2016). 
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Figure 3. MAT Utilization and Reimbursement Among High Mortality States (2016). 
 
 
Figure 4. MAT Utilization and Reimbursement Among Low Mortality States (2016). 
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Tables 
 
Table 1. Mean Differences in Physician Capacity by Medicaid Expansion group (2016).  
 
 
Table 2. Mean Differences in Physician Capacity by Medicaid Expansion group (2015)  
 
 
Mean of 30-
Patient Waiver 
rate 
Mean of 100-
Patient Waiver 
rate 
Mean of Opioid 
Treatment Program 
rate 
Medicaid  Expansion 
States (n=30) 
14.92± 4.04 6.58± 1.88 847.81± 756.36 
Non-Medicaid Expansion 
States (n=21) 
9.36± 3.73 3.92± 1.37 388.60± 300.87 
P(T<t) p=0.0264 p=0.0180 p=0.8388 
 
 
Table 3. Mean Differences in Physician Capacity by Medicaid Expansion group (2014)  
 Mean of 30-
Patient Waiver 
rate 
Mean of 100-
Patient Waiver 
rate 
Mean of Opioid 
Treatment Program 
rate 
Medicaid Expansion 
States (n=27) 
12.01± 2.98 5.84± 1.80 801.79± 756.41 
Non-Medicaid Expansion 
States (n=24) 
7.60± 2.17 4.05± 1.66 395.06± 273.69 
P(T<t) p=0.0097 p=0.1154 p=0.1631 
 
Table 4. Proportion of Medicaid Expansion States by 30-Patient Waiver Rate. (2014-
2016) 
Year 2016  2015  2014 
Quartile 
(% 
Medicaid 
Expansion 
States) 
Q1 
(53.8) 
Q2 
(53.8) 
Q3 
(58.3) 
Q4 
(84.6) 
Q1 
(30.8) 
Q2 
(53.8) 
Q3 
(75) 
Q4 
(76.9) 
Q1 
(53.8) 
Q2 
(15.4) 
Q3 
(66.7) 
Q4 
(76.9) 
P(|Z| > |z|) 0.442 0.442 0.641 0.029 0.017 0.664 0.096 0.062 0.530 0.002 0.138 0,022 
 
 
 
Mean of 30-
Patient Waiver 
rate 
Mean of 100-
Patient Waiver 
rate 
Mean of Opioid 
Treatment Program rate 
Medicaid  Expansion 
States (n=32) 
21.74± 6.93 7.22± 1.73 369.63± 364.4 
Non-Medicaid Expansion 
States (n=19) 
15.05± 7.38 4.73± 1.99 234.36± 222.14 
P(T<t) p=0.1013 p=0.0333 p=0.2928 
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Table 5. Proportion of Medicaid Expansion States by 100-Patient Waiver Rate. (2014-
2016) 
Year 2016  2015  2014 
Quartile 
(% 
Medicaid 
Expansion 
States) 
Q1 
(53.8) 
 
Q2 
(53.8) 
Q3 
(58.3) 
Q4 
(84.6) 
Q1 
(38.5) 
Q2 
(46.2) 
Q3 
(66.7) 
Q4 
(76.9) 
Q1 
(46.2) 
Q2 
(53.8) 
 
Q3 
(.50) 
Q4 
(69.2) 
P(|Z| > |z|) 0.442 0.442 0.641 0.029 0.028 0.282 0.234 0.062 0.113 0.470 0.408 0,086 
 
 
Table 6. Mean Differences in Buprenorphine Waiver Rates by Substance Use Disorder 
Risk Assessment Group (2016) 
 Mean of 30-Patient Waiver 
rate 
Mean of 100-Patient Waiver 
rate 
States with Assessment 
Policy (n=33) 
19.72± 5.74 7.24± 1.71 
States without Assessment 
Policy (n=19) 
18.39± 10.64 4.56± 1.97 
Pr(T<t) p=0.4015 p=0.0249 
 
Table 7. 2016 Age Adjusted Opioid Overdose Death Rate by 30 Patient Waived 
Quartiles 
Quartile Mean Standard 
Deviation 
Confidence Interval 
Quartile 4 29.18 1.929842 22.94814 35.42109 
Quartile 3 21.88 1.37833 17.00273 26.74727 
Quartile 2 19.13 2.471079 16.41309 21.84845 
Quartile 1 15.11 3.162964 11.30259 18.9128 
 
Table 8. 2016 Age Adjusted Opioid Overdose Death Rate by 100 Patient Waived 
Quartiles 
Quartile Mean Standard 
Deviation 
Confidence Interval 
Quartile 4 31.04615 2.478539 26.15917 35.93314 
Quartile 3 23.075 2.574794 17.99823 28.15177 
Quartile 2 18 1.194539 15.64471 20.35529 
Quartile 1 13.26923 1.403265 10.50239 16.03607 
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Table 9. 2016 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (23.50-89.83) AK, CT, DC, MA, ME, NH, NM, OH, OR, RI, VT, WA, WV 
Quartile 3 (13.56-21.70) CA, HI, ID, KY, MD, NC, NV, NY, PA, UT, WI, WY, XX 
Quartile 2 (9.27-13.37) AL, AZ, CO, FL, IN, LA, MI, MN, OK, SC, SD, TN, VA 
Quartile 1 (2.65-8.91)  
XX=17.86159659 
AR, DE, GA, IA, IL, KS, MO, MS, MT, ND, NE, NJ, TX 
XX= National Average  
 
Table 10. 2016 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (9.25-17.6) AL, CT, KY, MA, MD, ME, NH, NM, PA, RI, TN, VT, WV 
Quartile 3 (4.85-9.05) AR, DC, DE, FL, ID, LA, NC, NY, OH, OK, OR, UT, XX 
Quartile 2 (3.30-4.82) CO, GA, IN, MI, MN, MS, NJ, NV, SC, VA, WA, WI, WY 
Quartile 1 (0-3.18) AK, AZ, CA, HI, IA, IL, KS, MO, MT, ND, NE, SD, TX 
XX= National Average  
 
Table 11. 2015 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (17.05-59.25) AK, DC, DE, KY, MA, MD, ME, NH, NM, RI, TN, VT, WA  
Quartile 3 (9.47-16.49) AL, CT, FL, IN, NJ, NY, OH, OR, PA, SC, UT, WV, XX 
Quartile 2 (5.68-9.45) AZ, CA, CO, GA, ID, IL, LA, MN, MO, NC, ND, NV, VA 
Quartile 1 (0.97-5.66)  
XX=12.29253474 
AR, HI, IA, KS, MI, MS, MT, NE, OK, SD, TX, WI, WY 
XX= National Average  
 
Table 12. 2015 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (7.81 -20.02) AK, AL, KY, MA, ME, NH, NM, OH, PA, RI, TN, VT, WV 
Quartile 3 (4.39-7.73) CT, DC, DE, FL, IN, LA, MD, NC, NY, OR, UT, WA, XX 
Quartile 2 (2.37-4.37) CA, CO, GA, ID, MI, MN, MO, ND, NJ, SC, VA, WI, WY 
Quartile 1 (0-2.28) 
XX= 
AR, AZ, HI, IA, IL, KS, MS, MT, NE, NV, OK, SD, TX 
XX= National Average  
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Table 13. 2014 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (14.75-28.77) AK, DC, DE, KY, MA, MD, ME, NH, NM, OH, TN, VT, WA 
Quartile 3 (7.05-14.07) AL, CO, CT, HI, NJ, NY, OR, PA, RI, UT, VA, WV, XX 
Quartile 2 (5.31-7.04) CA, FL, GA, ID, IN, KS, LA, MN, MO, NC, NE, OK, SC 
Quartile 1 (0.98-4.87)  
XX=9.78156987 
AR, AZ, IA, IL, MI, MS, MT, ND, NV, SD, TX, WI, WY 
XX= National Average  
 
Table 14. 2014 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (6.77-18.82) AK, DE, KY, MA, ME, NH, NM, OH, PA, RI, TN, VT, WV 
Quartile 3 (3.85-6.46) AL, CT, DC, IN, LA, MD, MI, MS, ND, NY, SC, VA, XX 
Quartile 2 (2.22-3.82) AZ, CA, CO, FL, MN, MT, NC, NJ, OK, OR, UT, WA, WI 
Quartile 1 (0.32-2.18) 
XX= 
AR, GA, HI, IA, ID, IL, KS, MO, NE, NV, SD, TX, WY 
XX= National Average  
 
Table 15. 2013 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (12.81-27.15) AK, CT, DC, KY, MA, MD, ME, NM, NY, RI, VT, WA, WV 
Quartile 3 (8.29-12.05) AL, CA, DE, LA, NH, NJ, OH, OR, PA, TN, UT, VA, XX 
Quartile 2 (4.53-7.88)  AZ, CO, FL, GA, IL, IN, MI, NC, ND, NV, SC, WI, WY 
Quartile 1 (1.61-4.47) 
XX= 
AR, HI, IA, ID, KS, MN, MO, MS, MT, NE, OK, SD, TX 
XX= National Average  
 
Table 16. 2013 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (6.49-17.57) AK, CT, DE, KY, LA, MA, MD, ME, NM, OH, VT, WV, WY 
Quartile 3 (3.32-5.87) AL, FL, MS, NC, NH, NJ, NY, PA, RI, SC, TN, WA, XX 
Quartile 2 (1.86-3.23) AZ, CO, ID, IN, KS, MI, NV, OK, OR, TX, UT, VA, WI 
Quartile 1 (0-1.80) 
XX= 
AR, CA, DC, GA, HI, IA, IL, MN, MO, MT, ND, NE, SD 
XX= National Average 
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Table 17. 2012 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (10.91-21.90) AK, CT, DC, DE, KY, MA, MD, ME, NM, RI, VT, WV, WY 
Quartile 3 (6.52-10.80) FL, LA, NH, NJ, NY, OH, OR, PA, SC, TN, UT, WA, XX 
Quartile 2 (5.03-6.18) AZ, CA, CO, GA, HI, ID, IN, MI, MS, NC, OK, VA, WI 
Quartile 1 (1.95-4.98) 
XX=7.309073807 
 
AL, AR, IA, IL, KS, MN, MO, MT, ND, NE, NV, SD, TX 
XX= National Average 
 
Table 18. 2012 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (4.59-9.58) AK, DC, DE, KY, MA, MD, ME, NM, OH, PA, RI, VT, WV 
Quartile 3 (2.80-4.36) AL, CT, HI, IN, LA, NC, NH, NJ, NY, TN, UT, WI, WY 
Quartile 2 (1.53-2.77) AZ, CO, FL, KS,  MI, MS, NV, OR, SC, TX, VA, WA, XX 
Quartile 1 (0-1.46) 
XX=2.773945 
AR, CA, GA, IA, ID, IL, MN, MO, MT, ND, NE, OK, SD 
XX= National Average 
 
Table 19. 2011 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (9.83-22.14) AK, CT, DC, HI, KY, MA, ME, NM, NY, OR, PA, VT, WA 
Quartile 3 (6.27-9.59) AL, CA, DE, FL, KS, MD, NH, NJ, OH, RI, UT, WI, XX 
Quartile 2 (3.34-5.90) AZ, CO, GA, IL, IN, LA, MI, MS, NC, TN, VA, WV, WY 
Quartile 1 (0-3.21) 
XX=6.809045 
 
AR, IA, ID, MN, MO, MT, ND, NE, NV, OK, SC, SD, TX 
XX= National Average 
 
Table 20. 2011 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (4.55-12.78) AL, CT, DC, DE, MA, ME, MS, NH, NM, PA, RI, VT, WV 
Quartile 3 (2.35-4.53) AK, FL, KY, LA, MD, NV, NY, OH, OR, TN, UT, WA, XX 
Quartile 2 (1.46-2.16) AZ, CA, CO, IN, MI, MO, MT, NC, ND, NJ, OK, VA, WI 
Quartile 1 (0-1.45) 
XX=2.541359 
 
AR, GA, HI, IA, ID, IL, KS, MN, NE, SC, SD, TX, WY 
XX= National Average 
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Table 21. 2010 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (10.53-26.59) AK, CT, DE, MA, MD, ME, NH, NM, NY, PA, RI, WA, WV 
Quartile 3 (6.48-9.92) AL, DC, FL, HI, KY, MI, NJ, NV, OR, TN, UT, WY, XX 
Quartile 2 (4.47-6.39) CA, CO, GA, IN, LA, MN, MT, NC, OH, OK, VA, VT, WI 
Quartile 1 (1.23-4.44) 
XX=7.19277 
 
AR, AZ, IA, ID, IL, KS, MO, MS, ND, NE, SC, SD, TX 
XX= National Average 
 
Table 22. 2010 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (5.33-12.81) CT, DE, MA, MD, ME, NJ, NM, NV, NY, PA, RI, TN, WV 
Quartile 3 (3.31-5.16) AL, AR, DC, FL, KY, LA, MI, MS, NH, OH, OR, VT, XX 
Quartile 2 (2.02-3.24) AZ, CA, CO, GA, ID, IN, MO, MT, NC,TX, UT, WA, WI 
Quartile 1 (0-1.99) 
XX=3.539812 
 
AK, HI, IA, IL, KS, MN, ND, NE, OK, SC, SD, VA, WY 
XX= National Average 
 
Table 23. 2009 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (9.13-16.20) AK, DC, FL, HI, MA, MD, ME, NJ, NW, NY, PA, VT, WV 
Quartile 3 (7.20-9.05) AL, CO, CT, KY, MI, NH, NV, OR, RI, SC, TN, UT, WA 
Quartile 2 (4.23-7.06) AZ, CA, DE, GA, KS, LA, MS, NC, OH, OK, TX, WI, XX 
Quartile 1 (0.66-4.07) 
XX=7.060629 
AR, IA, ID, IL, IN, MN, MO, MT, ND, NE, SC, VA, WY 
XX= National Average 
 
Table 24. 2009 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (3.99-9.20) FL, KY, LA, MA, MD, ME, MI, MT, NY, RI, UT, VT, WV 
Quartile 3 (2.70-3.93) AL, CT, GA, MS, NH, NJ, OH, OR, PA, TN, WA, XX 
Quartile 2 (1.54-2.69) CA, CO, IL, IN, KS, MN, MO, NC, NM, OK, SC, VA, WI 
Quartile 1 (0-1.50) 
XX=2.917481 
AR, AZ, DC, DE, HI, IA, ID, ND, NE, NV, SD, TX, WY 
XX= National Average 
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Table 25. 2008DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (14.58-29.38) AK, CT, MA, MD, ME, MI, NJ, NM, NV, NY, RI, VT, WV 
Quartile 3 (9.84-13.64) AZ, CA, DC, FL, KY, LA, MS, OR, PA, TN, UT, WA, XX 
Quartile 2 (6.08-8.21) AL, CO, GA, IL, IN, MN, MT, ND, OH, SD, TX, VA, WI 
Quartile 1 (1.30-6.00) 
XX=10.55266 
AR, DE, HI, IA, ID, KS, MO, NC, NE, NH, OK, SC, WY 
XX= National Average 
 
Table 26. 2008 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (2.86-8.27) CT, FL, ID, KY, ME, NY, PA, RI, SC, TN, UT, VT, WV 
Quartile 3 (1.72-2.81) CO, DC, GA, IN, MA, MD, MI, NJ, NM, OH, WA, WY, XX 
Quartile 2 (1.15-1.70) AK, AL, AZ, CA, HI, LA, MO, MS, NC, ND, NV, VA, WI 
Quartile 1 (0-1.13) 
XX=1.979651 
AR, DE, IA, IL, KS, MN, MT, NE, NH, OK, OR, SD, TX 
XX= National Average 
 
Table 27. 2007 DATA Waived Physicians (per 1,000,000 residents), 30 Patients, States 
by Quartile 
Quartile and Range State 
Quartile 4 (11.27-24.37) AK, CT, DC, FL, MA, MD, ME, NJ, NM, NV, NY, PA, UT 
Quartile 3 (8.24-11.23) AL, AZ, DE, GA, HI, LA, MI, NE, RI, VT, WA, WI, WY 
Quartile 2 (6.24-8.08) CA, CO, KS, KY, MN, NC, OH, OR, TN, TX, VA, WV, XX 
Quartile 1 (1.10-6.06) 
XX=7.618733 
AR, IA, ID, IL, IN, MO, MS, MT, ND, NH, OK, SC, SD 
XX= National Average 
 
Table 28. 2007 DATA Waived Physicians (per 1,000,000 residents), 100 Patients, 
States by Quartile 
Quartile and Range State 
Quartile 4 (7.77-25.66) CT, LA, MA, MD, ME, MI, NH, NJ, NY, PA, RI, UT, VT 
Quartile 3 (5.65-7.63) AL, CA, DC, DE, FL, KY, MS, MT, OH, TN, WI, WV 
Quartile 2 (3.46-5.55) AZ, CO, GA, HI, IL, NC, NM, NV, OR, SC, VA, WA, WY 
Quartile 1 (0.47-3.23) 
XX=2.891467 
AR, IA, ID, IN, KS, MN, MO, ND, NE, OK, SD, TX, XX 
XX= National Average 
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Table 29. 2016 Opioid Overdose Mortality Rate (per 100,000 residents), States by 
Quartile 
Quartile and Range State 
Quartile 4 (25.2-52) CT, DC, DE, KY, MA, MD, ME, NH, NM, OH, PA, RI, WV 
Quartile 3 (20.3-24.85) AZ, FL, IN, LA, MI, MO, NJ, NV, OK, TN, UT, VT,  
Quartile 2 (14.5-19.7) AK, AL, AR, CO, ID, IL, NC, NY, VA, WA, WI, WY 
Quartile 1 (6.4-13.65) CA, GA, HI, IA, KS, MN, MS, MT, ND, NE, OR, SC, SD, 
TX, 
 
Table 30. 2015 Opioid Overdose Mortality Rate (per 100,000 residents), States by 
Quartile 
Quartile and Range State 
Quartile 4 (22-41.5) CT, DE, KY, MA, ME, NH, NM, OH, PA, RI, TN, UT, WV 
Quartile 3 (16.7-21.05) AZ, DC, IN, LA, MD, MI, MO, NJ, NV, OK, VT, WY 
Quartile 2 (13.8-16.2) AK, AL, AR, CO, FL, ID, IL, MT, NC, NY, SC, WA, WI 
Quartile 1 (6.9-13.5) CA, GA, HI, IA, KS, MN, MS, ND, NE, OR, SD, TX, VA  
 
Table 31. 2014 Opioid Overdose Mortality Rate (per 100,000 residents), States by 
Quartile 
Quartile and Range State 
Quartile 4 (19.4-35,5) DE, KY, MA, NH, NM, OH, OK, PA, RI, TN, UT, WV, WY 
Quartile 3 (16.3-18.7) AK, AL, AZ, CO, CT, IN, LA, MD, ME, MI, MO, NV 
Quartile 2 (12.4-15.1) AR, DC, FL, ID, IL, MT, NC, NJ, OR, SC, VT, WA, WI 
Quartile 1 (7.2-12.15) CA, GA, HI, IA, KS, MN, MS, ND, NE, NY, SD, TX, VA 
 
Table 32. 2013 Opioid Overdose Mortality Rate (per 100,000 residents), States by 
Quartile 
Quartile and Range State 
Quartile 4 (17.8-32.2) AZ, DE, KY, LA, NM, NV, OH, OK, PA, RI, TN, UT, WV 
Quartile 3 (14.6-17.65) CO, CT, DC, IN, MA, MD, MI, MO, NH, VT, WI, WY 
Quartile 2 (12-14.5) AK, AL, FL, ID, IL, KS, ME, MT, NC, NJ, SC, WA 
Quartile 1 (2.8-11.3) AR, CA, GA, HI, IA, MN, MS, ND, NE, NY, OR, SD, TX, VA 
 
 
